Climb Bio (CLYM) FY2025 10-K Risk Factors: 31 New, 42 Dropped

What the changes say

Climb Bio faces heightened trade tariff risks, especially on imported drug materials from China under new 2025 administration proposals.
Cash reserves of $160.7 million are projected to fund operations into 2028, but heavy milestone payment obligations continue.
International expansion introduces complex global privacy, tax, and regulatory hurdles.

What changed since the prior 10-K

New

NewRisks Related to our Financial Position and Need for Additional Capital
If we are unable to access capital when needed, it could force us to delay, reduce or terminate our product candidate development programs, commercialization efforts, or other operations
The company held $160.7 million in cash and marketable securities as of December 31, 2025, which it projects will fund operations into 2028.
NewRisks Related to our Financial Position and Need for Additional Capital
We may be required to make significant payments in connection with our license agreements, which could strain our capital resources
The company may face severe capital strain from milestone, royalty, and license obligations under agreements including the Mabworks Agreement for CLYM116 and legacy Tenet contracts.
NewRisks Related to our Business and the Development of our Product Candidates
Additionally, advertising and promotion of any product candidate that obtains approval outside of the U.S. will be heavily scrutinized by relevant foreign regulatory authorities
Foreign regulatory authorities will heavily scrutinize advertising and promotion of product candidates approved outside the U.S.
NewRisks Related to Legal and Regulatory Compliance
Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs
Compliance with healthcare fraud, abuse, and other laws will involve substantial costs and risk of penalties such as Medicare exclusion.
NewRisks Related to Legal and Regulatory Compliance
Actual or alleged non‑compliance by us could result in investigations, significant civil or criminal penalties, exclusion of our company from government programs, reputational harm, and operational restrictions. Non-compliance could adversely affect our ability to operate our business and our results of operations
Processing sensitive health and clinical trial data subjects the company to stringent U.S. and foreign data privacy and security regulations.
NewRisks Related to Legal and Regulatory Compliance
Outside the U.S., an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the GDPR impose strict requirements for processing the personal data of individuals, including sensitive data that we may process such as health data
The GDPR imposes strict requirements for processing personal and health data in Europe, requiring significant compliance resources.
NewRisks Related to Legal and Regulatory Compliance
For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens
Product candidates may qualify for Fast Track review or Breakthrough Therapy designation, allowing more frequent FDA interactions.
NewRisks Related to our Dependence on Third Parties
CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to any of our development programs
Reliance on third-party contract research organizations for clinical trials creates risks if they fail to perform or meet deadlines.
NewRisks Related to our Dependence on Third Parties
either scenario, our clinical trial supply could be delayed significantly as we establish alternative supply sources. These materials must meet stringent regulatory standards, making it difficult to quickly qualify alternative sources
Verifying alternative single-source manufacturers involves strict regulatory standards, making supply chain pivots difficult and costly.
NewRisks Related to our Dependence on Third Parties
The delays associated with the verification of a new third-party manufacturer could negatively affect our ability to develop or commercialize our drug product candidates in a timely manner or within budget
Changes in third-party manufacturers may require bridging studies and comparability testing to prove the new supply matches previous clinical trial material.
NewRisks Related to our Dependence on Third Parties
government. Such disruptions could have adverse effects on the development of our product candidates and our business operations
Proposed U.S. tariffs, including a 100% tariff announced by President Trump on imported patented drugs from China and elsewhere, could increase manufacturing costs.
NewRisks Related to Intellectual Property
we cannot be certain that such activities by CRH or other licensors will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights
The company has limited control over intellectual property defense and infringement proceedings conducted by licensors like CRH.
NewRisks Related to Intellectual Property
For example, under the Mabworks Agreement, Mabworks is responsible for prosecuting and maintaining intellectual property protection for CLYM116 in Greater China in consultation with us. We have not had and do not have primary control over these activities in Greater China for CLYM116
NewRisks Related to Intellectual Property
Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
NewRisks Related to Intellectual Property
Legal protections for proprietary intellectual property vary in jurisdictions throughout the world. The enforcement of intellectual property rights can be difficult and costly, and some jurisdictions provide weaker protection than the U.S
NewRisks Related to Intellectual Property
Patent terms may be inadequate to protect our competitive position on budoprutug, CLYM116 or any other product candidates for an adequate amount of time
NewRisks Related to Intellectual Property
budoprutug, CLYM116 or any other product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive medications, including generic medications
NewRisks Related to Intellectual Property
Any patent that may be issued from our owned pending patent applications relating to budoprutug is expected to expire in 2045, excluding any PTA that might be available following the grant of any such patent and any PTE that might be available following the grant of marketing authorizations
NewRisks Related to Intellectual Property
Any patent that may be issued from our co-owned pending patent applications relating to CLYM116 is expected to expire in 2046, excluding any PTA that might be available following the grant of any such patent and any PTE that might be available following the grant of marketing authorizations
NewRisks Related to Intellectual Property
Changes in patent law could diminish the value of our patents, thereby impairing our ability to protect our intellectual property for budoprutug, CLYM116 or any other product candidates
NewRisks Related to Intellectual Property
Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
NewRisks Related to Intellectual Property
We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources
NewRisks Related to Intellectual Property
Competitors may independently develop similar or alternative technologies, design around our patents, or benefit from aspects of our inventions that are not patentable or not protected. Intellectual property rights may not cover all threats, and the patents of others may adversely affect our business
NewRisks Related to our Business Operations and Employee Matters
If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan
NewRisks Related to our Business Operations and Employee Matters
Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements
NewRisks Related to our Business Operations and Employee Matters
and challenges in staffing and managing foreign operations. Political instability, public health emergencies, and other disruptions can further impact our ability to operate and grow outside the U.S
NewRisks Related to our Business Operations and Employee Matters
We may not be able to utilize a significant portion of our net operating loss carryforwards
NewRisks Related to our Common Stock
We have broad discretion in the use of our cash, cash equivalents and marketable securities and may not use them effectively
NewRisks Related to our Common Stock
in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions
NewRisks Related to our Common Stock
We are, have been, and may in the future become, involved in litigation that could result in significant costs, divert the attention of management and harm our business
NewRisks Related to our Common Stock
Even if we believe we have strong defenses, we may decide to settle claims for business or strategic reasons, particularly when the risks, costs, and burdens of litigation outweigh the potential benefits of continuing to defend a matter

Dropped

DroppedRisks Related to our Financial Position and Need for Additional Capital
We may be required to make significant payments to Mabworks in connection with the Mabworks Agreement
DroppedRisks Related to our Financial Position and Need for Additional Capital
We had cash, cash equivalents and marketable securities of $212.5 million and $106.8 million at December 31, 2024 and 2023, respectively
Payments to Mabworks in connection with the Mabworks Agreement.
DroppedRisks Related to our Financial Position and Need for Additional Capital
We may never generate the necessary data or results required to obtain marketing approval for our product candidates or generate revenue from the sale of any products for which we may obtain marketing approval
Cash position of $212.5 million at December 31, 2024 funding operations through 2027.
DroppedRisks Related to our Business and the Development of our Product Candidates
Under the Prescription Drug User Fee Act, the FDA’s standard review process for a BLA is meant to take 10 months from the date a BLA is accepted for filing, but that process may take longer to complete and FDA approval is never guaranteed
DroppedRisks Related to our Business and the Development of our Product Candidates
In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practice (cGMP) requirements and other regulations
DroppedRisks Related to our Business and the Development of our Product Candidates
In addition to potential changes to regulations as a result of legal challenges, these decisions may result in increased regulatory uncertainty and delays and other impacts, any of which could adversely impact our business and operations
DroppedRisks Related to our Business and the Development of our Product Candidates
Delays in the completion of any preclinical studies or clinical trials of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate product revenue
Generating necessary data or results to obtain marketing approval or revenue.
DroppedRisks Related to our Business and the Development of our Product Candidates
Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for our product candidates, the ability to obtain coverage and reimbursement, the ability to gain market share and whether we own the commercial rights for that territory
DroppedRisks Related to our Business and the Development of our Product Candidates
In addition, disruptions may result from events similar to the COVID-19 pandemic. During the COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA’s inability to complete required inspections for their applications
DroppedRisks Related to Legal and Regulatory Compliance
The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023
Prescription Drug User Fee Act 10-month review timelines and trial requirements.
DroppedRisks Related to Legal and Regulatory Compliance
European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers
DroppedRisks Related to Legal and Regulatory Compliance
Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired
DroppedRisks Related to Legal and Regulatory Compliance
Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf
DroppedRisks Related to Legal and Regulatory Compliance
If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences
FDA and regulatory inspections for cGMP compliance.
DroppedRisks Related to Legal and Regulatory Compliance
These designations are within the discretion of the FDA. Accordingly, even if we believe that our product candidates meet the criteria for these designations, the FDA may disagree and instead determine not to make such designation
DroppedRisks Related to Legal and Regulatory Compliance
Prior to seeking such accelerated approval, we will seek feedback from the FDA and otherwise evaluate our ability to seek and receive such accelerated approval
Regulatory uncertainty and delays from legal challenges like the mifepristone ruling.
DroppedRisks Related to Legal and Regulatory Compliance
There can be no assurance that the FDA will agree with any proposed surrogate endpoints or that we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval for our product candidates
DroppedRisks Related to Legal and Regulatory Compliance
We plan to conduct one or more clinical trials with one or more trial sites that are located outside the U.S. The acceptance by the FDA or other regulatory authorities of trial data from clinical trials conducted outside their jurisdiction may be subject to certain conditions or may not be accepted at all
Preclinical and clinical trial completion delays increasing costs.
DroppedRisks Related to our Dependence on Third Parties
We expect to rely on third-party CROs to conduct, supervise, and monitor our future preclinical studies and clinical trials for our product candidates, and we do not currently plan to independently conduct preclinical studies or future clinical trials of any other potential product candidates
DroppedRisks Related to our Dependence on Third Parties
Moreover, these agreements might terminate for various reasons, including a failure to perform by the third parties; if we need to enter into alternative arrangements, that will delay our product development activities and harm our business
DroppedRisks Related to our Dependence on Third Parties
In addition, if and when we have an approved product, we will be required to report certain financial interests of our third-party investigators if these relationships exceed certain financial thresholds or meet other criteria
DroppedRisks Related to our Dependence on Third Parties
If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms
DroppedRisks Related to our Dependence on Third Parties
We do not have any manufacturing facilities. We currently rely and expect to continue to rely on third-party manufacturers for the manufacture of our product candidates for nonclinical and clinical testing and for commercial supply, if approved
DroppedRisks Related to our Dependence on Third Parties
In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators
DroppedRisks Related to Intellectual Property
Because we will rely on third parties to develop and manufacture budoprutug, CLYM116, and any other product candidates, we must, at times, share trade secrets with them
DroppedRisks Related to Intellectual Property
In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights
DroppedRisks Related to Intellectual Property
We may not be able to protect our intellectual property rights throughout the world
Revenue dependence on addressable patient market size and drug pricing.
DroppedRisks Related to Intellectual Property
Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions
DroppedRisks Related to Intellectual Property
If we fail to comply with our obligations under the license agreement, Mabworks may have the right to terminate the license agreement, in which case, we may not be able to market or develop CLYM116
Potential disruptions from public health emergencies like COVID-19.
DroppedRisks Related to Intellectual Property
our right to sublicense patents and other rights to third parties;
DroppedRisks Related to Intellectual Property
Our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry is inherently uncertain, due in part to ongoing changes in the patent laws
Medicare Drug Price Negotiation Program implementation details.
DroppedRisks Related to Intellectual Property
If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel
DroppedRisks Related to Intellectual Property
Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities
European and foreign law equivalents regarding healthcare provider payment reporting.
DroppedRisks Related to Intellectual Property
If we or our licensors do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized
Sanctions and exclusions of healthcare providers impacting business operations.
DroppedRisks Related to Intellectual Property
During the trademark registration process, we may receive Office Actions from the USPTO or from comparable agencies in foreign jurisdictions objecting to the registration of our trademark. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections
DroppedRisks Related to our Business Operations and Employee Matters
During times of war and other major conflicts, we, and the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and harm our business
DroppedRisks Related to our Business Operations and Employee Matters
Our ability to compete in the highly competitive pharmaceuticals industry depends on our ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. We are highly dependent on recruiting and retaining our management and scientific personnel
DroppedRisks Related to our Business Operations and Employee Matters
We are exposed to the risk that our employees, independent contractors, consultants, licensors, commercial collaborators, principal investigators, CROs and vendors may engage in fraudulent conduct or other illegal activity
DroppedRisks Related to our Business Operations and Employee Matters
As of December 31, 2024, we had net operating loss (NOL) carryforwards of approximately $23.3 million for federal income tax purposes, $68.6 million for foreign income tax purposes and $10.7 million for state income tax purposes
DroppedRisks Related to our Common Stock
Our management has broad discretion in the application of our cash, cash equivalents and marketable securities and could use such funds in ways that do not improve our results of operations or enhance the value of our common stock or in ways that our stockholders may not agree with
DroppedRisks Related to our Common Stock
We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification
DroppedRisks Related to our Common Stock
Securities litigation or stockholder derivative litigation frequently follows the announcement of certain significant business transactions, such as the sale of a business division or announcement of an acquisition or a business combination transaction

Reworded

100% rewrittenRisks Related to our Business Operations and Employee Matters
Our international operations may expose us to business, regulatory, political, operational, financial, pricing and reimbursement risks associated with doing business outside of the U.S
Added specific mention of foreign exchange, logistics, geopolitical exposure, and anti-corruption issues alongside international regulatory and pricing complexities.
Was: Any international operations we may have exposes us to business, regulatory, political, operational, financial, pricing and reimbursement risks associated with doing business outside of the U.S
99% rewrittenRisks Related to our Common Stock
Changes in tax laws or regulations that are applied adversely to us may seriously harm our business
Added specific reference to U.S. legislation such as the One Big Beautiful Bill Act alongside OECD Pillar Two rules.
98% rewrittenRisks Related to our Common Stock
If equity research analysts publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
Streamlined language regarding equity research analyst coverage and its impact on stock price and trading volume.
Was: If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
96% rewrittenRisks Related to Intellectual Property
Purchase Agreement), including our rights to the licenses subject to the Asset Purchase Agreement, in which case, we may not be able to market or develop such Product
Clarified consequences of failing to meet Mabworks license obligations, including potential market loss or competitor access.
Was: If we fail to comply with our obligations under the asset purchase agreement, Acelyrin may have the right to re-purchase the obtained asset, including our rights to the licenses subject to the asset purchase agreement, in which case, we may not be able to market or develop budoprutug
95% rewrittenRisks Related to Legal and Regulatory Compliance
Accelerated approval by the FDA, even if granted for our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval
Expanded on accelerated approval and conditional authorization risks, including pre-approval readiness, confirmatory trials, and withdrawal if benefit is unverified.
94% rewrittenRisks Related to our Financial Position and Need for Additional Capital
We currently have no source of product revenue and may never become profitable
Clarified that revenue generation depends on successfully commercializing in-licensed, acquired, or internally developed products.
92% rewrittenRisks Related to our Business and the Development of our Product Candidates
seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall
Added civil, criminal, and administrative sanctions by the FDA or enforcement authorities for illegal advertising or promotion.
91% rewrittenRisks Related to Intellectual Property
Intellectual property rights do not necessarily address all potential threats
Added specific mention of alternative technologies, off-label use, safe-harbor R&D, and missed filings as threats that can erode intellectual property exclusivity.
89% rewrittenRisks Related to Intellectual Property
If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize our product candidates, which would have a material adverse effect on our business
87% rewrittenRisks Related to Intellectual Property
We may not be able to protect and enforce our trademarks and trade names or build name recognition in our markets of interest thereby harming our competitive position
87% rewrittenRisks Related to our Business and the Development of our Product Candidates
Our future success is dependent on the regulatory approval and commercialization of our product candidates, and if we are unable to successfully develop and commercialize our product candidates, or experience any delay in doing so, our business could be materially harmed
Was: Our future success is dependent primarily on the regulatory approval and commercialization of our product candidates
84% rewrittenRisks Related to our Dependence on Third Parties
Any performance failure on the part of our existing or future manufacturers could delay any potential clinical development or marketing approval of our product candidates. We do not currently have arrangements in place for redundant supply for bulk drug substances
83% rewrittenRisks Related to our Business and the Development of our Product Candidates
third parties being unwilling or unable to satisfy their contractual obligations to us
83% rewrittenRisks Related to our Business and the Development of our Product Candidates
We have no experience in sales, marketing and distribution and may have to enter into agreements with third parties to perform these functions, which could prevent us from successfully commercializing our product candidates
80% rewrittenRisks Related to our Financial Position and Need for Additional Capital
We have incurred significant losses since our inception, expect to continue to incur substantial losses for the foreseeable future and may never achieve or sustain profitability
Was: We have incurred significant losses since our inception and anticipate that we will incur substantial losses for the foreseeable future and may never achieve or maintain profitability
80% rewrittenRisks Related to Intellectual Property
We may be subject to claims by third parties asserting that we or our employees have infringed upon, misappropriated or otherwise violated their intellectual property rights, or claiming ownership of what we regard as our own intellectual property
79% rewrittenRisks Related to Intellectual Property
We cannot be certain that the USPTO and courts in the U.S. or the patent offices and courts in foreign countries will consider the claims in our patents and applications covering budoprutug, CLYM116 and any other product candidates as patentable
Was: We cannot be certain that the USPTO and courts in the U.S. or the patent offices and courts in foreign countries will consider the claims in our patents and applications covering budoprutug and any other product candidates as patentable
76% rewrittenRisks Related to our Dependence on Third Parties
Changes in and uncertainty surrounding U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results
Was: Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results
73% rewrittenRisks Related to Intellectual Property
We are a party to a number of license agreements under which we are granted rights to intellectual property that are important to our business, and we may enter into additional license agreements in the future for budoprutug, CLYM116 or any other product candidates
Was: We are a party to a number of license agreements under which we are granted rights to intellectual property that are important to our business, and we may enter into additional license agreements in the future for budoprutug or any other product candidates
67% rewrittenRisks Related to our Business and the Development of our Product Candidates
These estimates, and our estimates and forecasts relating to size and expected growth based on these estimates, may prove to be incorrect and new studies may reduce the estimated incidence or prevalence of these diseases
66% rewrittenRisks Related to our Business and the Development of our Product Candidates
Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties
66% rewrittenRisks Related to Legal and Regulatory Compliance
Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval and commercialize our product candidates, if and when approved, and may affect the prices we may charge for such product candidates, if and when approved
61% rewrittenRisks Related to Legal and Regulatory Compliance
If approved, our product candidates regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway
60% rewrittenRisks Related to Intellectual Property
Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could negatively impact the success of our business
57% rewrittenRisks Related to Intellectual Property
Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements
55% rewrittenRisks Related to our Common Stock
We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents. Claims for indemnification may reduce our available funds to satisfy third-party claims or to invest in our business
Was: We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents
50% rewrittenRisks Related to Intellectual Property
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
49% rewrittenRisks Related to our Dependence on Third Parties
We will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. We cannot predict the success of any collaboration that we have entered into or will enter into
49% rewrittenRisks Related to Legal and Regulatory Compliance
Our failure to obtain regulatory approval in foreign jurisdictions would prevent us from marketing our product candidates outside the U.S
43% rewrittenRisks Related to Intellectual Property
the amounts of royalties, milestones or other payments due under the license agreement
41% rewrittenRisks Related to our Common Stock
Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be our stockholders’ sole source of gain
Was: Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain
41% rewrittenRisks Related to our Dependence on Third Parties
We may not have access to the raw materials and other components necessary for the manufacturing of our product candidates
40% rewrittenRisks Related to Intellectual Property
We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market our product candidates
39% rewrittenRisks Related to our Common Stock
A significant portion of our common stock may be sold into the market, which could cause the market price of our common stock to drop significantly
38% rewrittenRisks Related to our Business Operations and Employee Matters
certain expenses including, among others, expenses for travel and insurance; and
37% rewrittenRisks Related to Legal and Regulatory Compliance
We have received orphan drug designation for budoprutug for the treatment of pMN, but we may be unable to realize the benefits associated with orphan drug designation, including market exclusivity
35% rewrittenRisks Related to our Common Stock
Unfavorable global economic conditions could adversely affect our business, financial condition, stock price, and results of operations
34% rewrittenRisks Related to our Business Operations and Employee Matters
Security incidents and attendant consequences may cause delays in the development of our product candidates and negatively impact our ability to grow and operate our business
32% rewrittenRisks Related to our Common Stock
Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law
30% rewrittenRisks Related to our Financial Position and Need for Additional Capital
attract, hire and retain qualified personnel
29% rewrittenRisks Related to our Common Stock
If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
28% rewrittenRisks Related to our Common Stock
We are an “emerging growth company” and a “smaller reporting company,” and as a result of the reduced reporting requirements applicable to “emerging growth companies” and “smaller reporting companies,” our common stock may be less attractive to investors
27% rewrittenRisks Related to our Business and the Development of our Product Candidates
a continued acceptable safety profile of such product following approval
25% rewrittenRisks Related to our Business and the Development of our Product Candidates
the inability to commercialize our product candidates
25% rewrittenRisks Related to our Common Stock
Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock
24% rewrittenRisks Related to our Financial Position and Need for Additional Capital
Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or our product candidates
21% rewrittenRisks Related to Intellectual Property
The patent protection we obtain for budoprutug, CLYM116 or any other product candidates and technologies may be challenged and rendered invalid or unenforceable
Was: The patent protection we obtain for budoprutug or any other product candidates and technologies may be challenged and rendered invalid and/or unenforceable

All 104 risk factors

Headings as the filing states them, in filing order.

Risks Related to our Financial Position and Need for Additional Capital

01We have incurred significant losses since our inception, expect to continue to incur substantial losses for the foreseeable future and may never achieve or sustain profitability80% rewritten
02If we are unable to access capital when needed, it could force us to delay, reduce or terminate our product candidate development programs, commercialization efforts, or other operationsNew
03our efforts to enhance operational systems and hire personnel to support the development of our product candidates
04Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or our product candidates24% rewritten
05We currently have no source of product revenue and may never become profitable94% rewritten
06attract, hire and retain qualified personnel30% rewritten
07We may be required to make significant payments in connection with our license agreements, which could strain our capital resourcesNew

Risks Related to our Business and the Development of our Product Candidates

08Our future success is dependent on the regulatory approval and commercialization of our product candidates, and if we are unable to successfully develop and commercialize our product candidates, or experience any delay in doing so, our business could be materially harmed87% rewritten
09Obtaining regulatory approval for marketing of our product candidates in one country does not ensure we will be able to obtain regulatory approval in other countries, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in other countries
10a continued acceptable safety profile of such product following approval27% rewritten
11Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties66% rewritten
12seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall92% rewritten
13Additionally, advertising and promotion of any product candidate that obtains approval outside of the U.S. will be heavily scrutinized by relevant foreign regulatory authoritiesNew
14third parties being unwilling or unable to satisfy their contractual obligations to us83% rewritten
15Our product candidates may cause adverse events or undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any marketing approval
16If we encounter difficulties enrolling or retaining patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
17the risk that patients enrolled in clinical trials will drop out of the trials before completion
18We are also required to register certain clinical trials and post the results of completed clinical trials on a government-sponsored database, such as www.ClinicalTrials.gov in the U.S., within certain time frames. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions
19the inability to commercialize our product candidates25% rewritten
20Drug development is highly uncertain, and if we are unable to successfully develop and commercialize our product candidates, or experience significant delays in doing so, our business may be harmed
21Our estimates of market opportunity and forecasts of market growth for our product candidates may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all
22These estimates, and our estimates and forecasts relating to size and expected growth based on these estimates, may prove to be incorrect and new studies may reduce the estimated incidence or prevalence of these diseases67% rewritten
23We have no experience in sales, marketing and distribution and may have to enter into agreements with third parties to perform these functions, which could prevent us from successfully commercializing our product candidates83% rewritten

Risks Related to Legal and Regulatory Compliance

24Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval and commercialize our product candidates, if and when approved, and may affect the prices we may charge for such product candidates, if and when approved66% rewritten
25We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures
26Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costsNew
27Actual or alleged non‑compliance by us could result in investigations, significant civil or criminal penalties, exclusion of our company from government programs, reputational harm, and operational restrictions. Non-compliance could adversely affect our ability to operate our business and our results of operationsNew
28Outside the U.S., an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the GDPR impose strict requirements for processing the personal data of individuals, including sensitive data that we may process such as health dataNew
29For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimensNew
30Accelerated approval by the FDA, even if granted for our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval95% rewritten
31We have received orphan drug designation for budoprutug for the treatment of pMN, but we may be unable to realize the benefits associated with orphan drug designation, including market exclusivity37% rewritten
32If approved, our product candidates regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway61% rewritten
33Our failure to obtain regulatory approval in foreign jurisdictions would prevent us from marketing our product candidates outside the U.S49% rewritten

Risks Related to our Dependence on Third Parties

34CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to any of our development programsNew
35Any performance failure on the part of our existing or future manufacturers could delay any potential clinical development or marketing approval of our product candidates. We do not currently have arrangements in place for redundant supply for bulk drug substances84% rewritten
36either scenario, our clinical trial supply could be delayed significantly as we establish alternative supply sources. These materials must meet stringent regulatory standards, making it difficult to quickly qualify alternative sourcesNew
37The delays associated with the verification of a new third-party manufacturer could negatively affect our ability to develop or commercialize our drug product candidates in a timely manner or within budgetNew
38If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
39We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination
40We may not have access to the raw materials and other components necessary for the manufacturing of our product candidates41% rewritten
41If we are not able to establish future collaborations, we may have to alter some of our future development and commercialization plans
42We will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. We cannot predict the success of any collaboration that we have entered into or will enter into49% rewritten
43Changes in and uncertainty surrounding U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results76% rewritten
44government. Such disruptions could have adverse effects on the development of our product candidates and our business operationsNew

Risks Related to Intellectual Property

45We rely heavily on certain in-licensed patents and other intellectual property rights in connection with our development of our product candidates and may be required to acquire or license additional patents or other intellectual property rights to continue to develop and commercialize our product candidates
46We rely heavily on patents, know-how and other intellectual property licensed from others. We are party to license agreements with each of CRH and Mabworks pursuant to each of which we are granted rights to intellectual property that are important to budoprutug and CLYM116, respectively
47the amounts of royalties, milestones or other payments due under the license agreement43% rewritten
48Furthermore, other parties may successfully challenge, invalidate or circumvent our issued patents so that our patent rights do not create an effective competitive barrier or revenue source
49The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and abroad
50We cannot be certain that the USPTO and courts in the U.S. or the patent offices and courts in foreign countries will consider the claims in our patents and applications covering budoprutug, CLYM116 and any other product candidates as patentable79% rewritten
51we cannot be certain that such activities by CRH or other licensors will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rightsNew
52For example, under the Mabworks Agreement, Mabworks is responsible for prosecuting and maintaining intellectual property protection for CLYM116 in Greater China in consultation with us. We have not had and do not have primary control over these activities in Greater China for CLYM116New
53It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to its licensed technology in the event of misuse by the licensor
54The patent protection we obtain for budoprutug, CLYM116 or any other product candidates and technologies may be challenged and rendered invalid or unenforceable21% rewritten
55Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosedNew
56We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or other intellectual property, which could be expensive, time-consuming and unsuccessful, and issued patents covering our technology and product candidates could be found invalid or unenforceable if challenged
57Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately
58Legal protections for proprietary intellectual property vary in jurisdictions throughout the world. The enforcement of intellectual property rights can be difficult and costly, and some jurisdictions provide weaker protection than the U.SNew
59We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market our product candidates40% rewritten
60We are a party to a number of license agreements under which we are granted rights to intellectual property that are important to our business, and we may enter into additional license agreements in the future for budoprutug, CLYM116 or any other product candidates73% rewritten
61Purchase Agreement), including our rights to the licenses subject to the Asset Purchase Agreement, in which case, we may not be able to market or develop such Product96% rewritten
62If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize our product candidates, which would have a material adverse effect on our business89% rewritten
63Patent terms may be inadequate to protect our competitive position on budoprutug, CLYM116 or any other product candidates for an adequate amount of timeNew
64budoprutug, CLYM116 or any other product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive medications, including generic medicationsNew
65Any patent that may be issued from our owned pending patent applications relating to budoprutug is expected to expire in 2045, excluding any PTA that might be available following the grant of any such patent and any PTE that might be available following the grant of marketing authorizationsNew
66Any patent that may be issued from our co-owned pending patent applications relating to CLYM116 is expected to expire in 2046, excluding any PTA that might be available following the grant of any such patent and any PTE that might be available following the grant of marketing authorizationsNew
67Changes in patent law could diminish the value of our patents, thereby impairing our ability to protect our intellectual property for budoprutug, CLYM116 or any other product candidatesNew
68Therefore, there is increased uncertainty with regard to our ability to obtain patents in the future, as well as uncertainty with respect to the value of patents once obtained
69Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements57% rewritten
70Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could negatively impact the success of our business60% rewritten
71We may be subject to claims by third parties asserting that we or our employees have infringed upon, misappropriated or otherwise violated their intellectual property rights, or claiming ownership of what we regard as our own intellectual property80% rewritten
72Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilitiesNew
73We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resourcesNew
74If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed50% rewritten
75We may not be able to protect and enforce our trademarks and trade names or build name recognition in our markets of interest thereby harming our competitive position87% rewritten
76Intellectual property rights do not necessarily address all potential threats91% rewritten
77Competitors may independently develop similar or alternative technologies, design around our patents, or benefit from aspects of our inventions that are not patentable or not protected. Intellectual property rights may not cover all threats, and the patents of others may adversely affect our businessNew

Risks Related to our Business Operations and Employee Matters

78Security incidents and attendant consequences may cause delays in the development of our product candidates and negatively impact our ability to grow and operate our business34% rewritten
79If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business planNew
80Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirementsNew
81Our international operations may expose us to business, regulatory, political, operational, financial, pricing and reimbursement risks associated with doing business outside of the U.S100% rewritten
82and challenges in staffing and managing foreign operations. Political instability, public health emergencies, and other disruptions can further impact our ability to operate and grow outside the U.SNew
83certain expenses including, among others, expenses for travel and insurance; and38% rewritten
84We may not be able to utilize a significant portion of our net operating loss carryforwardsNew
85increased legal and accounting compliance costs

Risks Related to our Common Stock

86The trading price of our common stock has been and may continue to be volatile, and purchasers of our common stock could incur substantial losses
87other events or factors, including the other factors described in this “Risk Factors” section, many of which are beyond our control
88Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be our stockholders’ sole source of gain41% rewritten
89We have broad discretion in the use of our cash, cash equivalents and marketable securities and may not use them effectivelyNew
90A significant portion of our common stock may be sold into the market, which could cause the market price of our common stock to drop significantly39% rewritten
91We have registered and intend to continue to register all shares of common stock that we may issue under our equity compensation plans. These shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates
92Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock25% rewritten
93These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management
94Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law32% rewritten
95We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents. Claims for indemnification may reduce our available funds to satisfy third-party claims or to invest in our business55% rewritten
96If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired29% rewritten
97in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictionsNew
98We are, have been, and may in the future become, involved in litigation that could result in significant costs, divert the attention of management and harm our businessNew
99Even if we believe we have strong defenses, we may decide to settle claims for business or strategic reasons, particularly when the risks, costs, and burdens of litigation outweigh the potential benefits of continuing to defend a matterNew
100If equity research analysts publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline98% rewritten
101Unfavorable global economic conditions could adversely affect our business, financial condition, stock price, and results of operations35% rewritten
102We are an “emerging growth company” and a “smaller reporting company,” and as a result of the reduced reporting requirements applicable to “emerging growth companies” and “smaller reporting companies,” our common stock may be less attractive to investors28% rewritten
103We may be unable to maintain adequate insurance coverage
104Changes in tax laws or regulations that are applied adversely to us may seriously harm our business99% rewritten

Other Climb Bio 10-Ks

FY2024 10-K risk factors
115 risks
Climb Bio is a clinical-stage biotechnology company focused on developing budoprutug for immune-mediated diseases and CLYM116 for IgAN.
Filed Mar 25, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.